CN101501070B - 抗原性gm-csf肽和针对gm-csf的抗体 - Google Patents

抗原性gm-csf肽和针对gm-csf的抗体 Download PDF

Info

Publication number
CN101501070B
CN101501070B CN2007800048460A CN200780004846A CN101501070B CN 101501070 B CN101501070 B CN 101501070B CN 2007800048460 A CN2007800048460 A CN 2007800048460A CN 200780004846 A CN200780004846 A CN 200780004846A CN 101501070 B CN101501070 B CN 101501070B
Authority
CN
China
Prior art keywords
seq
csf
cells
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800048460A
Other languages
English (en)
Chinese (zh)
Other versions
CN101501070A (zh
Inventor
菲利普·M·萨斯
尼古拉斯·C·尼古拉德斯
路易吉·格拉索
李健
巢麒敏
埃里克·鲁蒂埃
沃尔夫冈·埃贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101501070(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of CN101501070A publication Critical patent/CN101501070A/zh
Application granted granted Critical
Publication of CN101501070B publication Critical patent/CN101501070B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
CN2007800048460A 2006-02-08 2007-02-08 抗原性gm-csf肽和针对gm-csf的抗体 Active CN101501070B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77125106P 2006-02-08 2006-02-08
US60/771,251 2006-02-08
US77450006P 2006-02-17 2006-02-17
US60/774,500 2006-02-17
PCT/US2007/061874 WO2007092939A2 (en) 2006-02-08 2007-02-08 Antigenic gm-csf peptides and antibodies to gm-csf

Publications (2)

Publication Number Publication Date
CN101501070A CN101501070A (zh) 2009-08-05
CN101501070B true CN101501070B (zh) 2013-12-25

Family

ID=38345964

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800048460A Active CN101501070B (zh) 2006-02-08 2007-02-08 抗原性gm-csf肽和针对gm-csf的抗体

Country Status (18)

Country Link
US (5) US7741450B2 (enExample)
EP (2) EP1981909B1 (enExample)
JP (1) JP5210889B2 (enExample)
KR (2) KR101395515B1 (enExample)
CN (1) CN101501070B (enExample)
AU (1) AU2007213716C1 (enExample)
CA (2) CA2641169C (enExample)
CY (1) CY1118709T1 (enExample)
DK (1) DK1981909T3 (enExample)
ES (1) ES2609088T3 (enExample)
HR (1) HRP20170024T1 (enExample)
HU (1) HUE032584T2 (enExample)
IL (2) IL193011A (enExample)
LT (1) LT1981909T (enExample)
PL (1) PL1981909T3 (enExample)
PT (1) PT1981909T (enExample)
RS (1) RS55526B1 (enExample)
WO (1) WO2007092939A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
EP2013620A2 (en) * 2006-04-17 2009-01-14 Morphotek, Inc. Whole genome evolution technology applied to improve protein and antibody yields by cells
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
SI2769729T1 (sl) 2007-09-04 2019-06-28 Compugen Ltd. Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009062238A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
US8679502B2 (en) * 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
JP5476310B2 (ja) * 2008-02-14 2014-04-23 株式会社イーベック ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
WO2009126659A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
KR101824512B1 (ko) * 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
CA2717987C (en) * 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2011100636A1 (en) * 2010-02-11 2011-08-18 The Board Of Trustees Of The Leland Stanford Junior University Markers for determination of patient responsiveness
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112013033944A2 (pt) * 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN106916783B (zh) * 2013-05-29 2020-07-17 中国科学院分子细胞科学卓越创新中心 肌肉干细胞体外培养方法及其应用
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
US11173208B2 (en) 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
ES2626491B1 (es) 2015-12-03 2018-06-25 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpos monoclonales frente a bambi y uso para tratamiento de enfermedades inflamatorias
DK3328887T3 (da) 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
WO2018227142A1 (en) 2017-06-09 2018-12-13 The Regents Of The University Of Colorado, A Body Corporate Gm-csf mimetics and methods of making and using same
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CN111757744A (zh) 2017-10-02 2020-10-09 人源股份有限公司 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
CN112805301B (zh) * 2018-10-15 2023-07-21 安立玺荣生医(香港)有限公司 粒细胞-巨噬细胞集落刺激因子的抗体及其用途
US12624086B2 (en) * 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
WO2021207667A1 (en) * 2020-04-10 2021-10-14 Kinevant Sciences Gmbh Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
CN117384856B (zh) * 2023-09-04 2024-04-16 广州医科大学 一种永生化copd人支气管上皮细胞株及其构建方法和应用
CN120399067B (zh) * 2025-07-02 2025-09-30 武汉伊莱瑞特生物科技股份有限公司 一种与人gm-csf特异性结合的单克隆抗体及其检测试剂盒和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86107666A (zh) * 1985-12-09 1987-09-30 柯瑞英-艾格公司 杂交瘤细胞系及其产生的抗人多能粒细胞集落刺激因子单克隆抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
NZ234479A (en) 1989-07-14 1992-03-26 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
BR9205151A (pt) 1992-08-17 1994-03-01 Praxair Technology Inc Dissolucao aumentada de gas
WO1997035559A2 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation
WO1997035882A1 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
EP0959136A1 (en) 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2002070548A2 (en) 2001-03-08 2002-09-12 Merck Patent Gmbh Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
WO2004046330A2 (en) * 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
JP2005040126A (ja) * 2003-02-28 2005-02-17 Mitsubishi Pharma Corp モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
KR20050106459A (ko) 2003-02-28 2005-11-09 미쯔비시 웰 파마 가부시키가이샤 단일클론 항체, 이를 코딩하는 유전자, 하이브리도마, 의약조성물 및 진단 시약
CA2534659A1 (en) 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
JP2005176792A (ja) 2003-12-24 2005-07-07 Atex Co Ltd 乗用草刈機
ATE435238T1 (de) * 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
ES2918209T3 (es) * 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86107666A (zh) * 1985-12-09 1987-09-30 柯瑞英-艾格公司 杂交瘤细胞系及其产生的抗人多能粒细胞集落刺激因子单克隆抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bonfield TL等.Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis.《Clinical Immunology》.2002,第105卷(第3期),342-350. *
Kanakura Y等.Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies.《Blood》.1991,第77卷(第5期),1033-1043. *

Also Published As

Publication number Publication date
ES2609088T3 (es) 2017-04-18
US20080292641A1 (en) 2008-11-27
KR20130124420A (ko) 2013-11-13
JP5210889B2 (ja) 2013-06-12
US20140086928A1 (en) 2014-03-27
US8318168B2 (en) 2012-11-27
IL235050A (en) 2017-03-30
EP3181585A3 (en) 2017-08-30
US20160333089A1 (en) 2016-11-17
EP1981909A2 (en) 2008-10-22
CA2961031A1 (en) 2007-08-16
EP1981909B1 (en) 2016-10-12
JP2009526082A (ja) 2009-07-16
CA2961031C (en) 2020-02-25
IL193011A0 (en) 2009-02-11
WO2007092939A2 (en) 2007-08-16
WO2007092939A8 (en) 2009-07-23
KR20080099314A (ko) 2008-11-12
WO2007092939A3 (en) 2008-03-27
AU2007213716A1 (en) 2007-08-16
DK1981909T3 (en) 2017-01-23
IL193011A (en) 2015-06-30
CA2641169A1 (en) 2007-08-16
US20100272730A1 (en) 2010-10-28
HUE032584T2 (en) 2017-09-28
AU2007213716C1 (en) 2015-05-07
US7741450B2 (en) 2010-06-22
LT1981909T (lt) 2017-01-10
PL1981909T3 (pl) 2017-08-31
CA2641169C (en) 2017-05-02
CY1118709T1 (el) 2017-07-12
US9422367B2 (en) 2016-08-23
KR101395515B1 (ko) 2014-05-14
KR101486183B1 (ko) 2015-01-28
RS55526B1 (sr) 2017-05-31
HRP20170024T1 (hr) 2017-03-10
EP3181585A2 (en) 2017-06-21
US10023632B2 (en) 2018-07-17
US8623364B2 (en) 2014-01-07
CN101501070A (zh) 2009-08-05
AU2007213716B2 (en) 2012-12-06
US20130058945A1 (en) 2013-03-07
PT1981909T (pt) 2017-01-18

Similar Documents

Publication Publication Date Title
JP5210889B2 (ja) 抗原性ｇｍ−ｃｓｆペプチドおよび抗ｇｍ−ｃｓｆ抗体
DK2311873T3 (en) M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
CN102892786B (zh) Pd-1抗体
CN110461877A (zh) 抗il-36r抗体联合治疗
JP2017014207A (ja) 筋肉増殖を増加させるための組成物および方法
US20130164292A1 (en) Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
AU2003286437A1 (en) HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
KR20080080639A (ko) 항-ｏｘ40ｌ 항체 및 그의 사용 방법
JP2008500806A5 (enExample)
JP2023113896A (ja) 抗ｍｓ４ａ６ａ抗体及びその使用方法
AU2013201228B2 (en) Antigenic gm-csf peptides and antibodies to gm-csf

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20181101

Address after: new jersey

Patentee after: Eisai Corp.

Address before: American Pennsylvania

Patentee before: Morphotek Inc.